Clinical Trials Logo

Salivary Duct Carcinoma clinical trials

View clinical trials related to Salivary Duct Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05513365 Recruiting - Clinical trials for Salivary Duct Carcinoma

Phase II Dutasteride in Combination With CAB vs CAB in SDC

DUCT
Start date: September 27, 2022
Phase: Phase 2
Study type: Interventional

Phase 2 clinical trial on the addition of dutasteride to combined androgen blockade (CAB) therapy in recurrent and/or metastatic (R/M) salivary duct carcinoma (SDC) patients. The study included two cohorts of patients: Cohort A, which comprises ADT-naïve patients, and Cohort B, which comprises ADT-resistant patients. Cohort A is closed for inclusion as of April 18, 2024.

NCT ID: NCT04291300 Completed - Clinical trials for Adenoid Cystic Carcinoma

Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

LUPSA
Start date: May 26, 2020
Phase: Phase 2
Study type: Interventional

Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.

NCT ID: NCT04249947 Active, not recruiting - Prostate Cancer Clinical Trials

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Start date: February 28, 2020
Phase: Phase 1
Study type: Interventional

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

NCT ID: NCT04214353 Recruiting - Clinical trials for Salivary Gland Cancer

PSMA-PET Imaging Before and After ADT in Advanced SDC Patients

ADT-SCAN
Start date: January 14, 2020
Phase: N/A
Study type: Interventional

Explorative study, which evaluates the effect of androgen deprivation therapy (ADT) on the PSMA ligand uptake on 68Ga-PSMA-PET/CT in salivary duct carcinoma patients.

NCT ID: NCT03614364 Active, not recruiting - Clinical trials for Salivary Duct Carcinoma

Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma

Start date: September 20, 2018
Phase: Phase 2
Study type: Interventional

1. Study outline This is a multicenter, single-arm, phase II trial to evaluate the efficacy and safety of nanoxel plus herzuma combination chemotherapy in patients with metastatic salivary ductal cancer. Approximately 41 patients will be enrolled. Treatment will be continued until disease progression or unacceptable toxicities. Response evaluation will be performed every 2 cycles. 2. Dosing & Treatment schedule D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks (In case of discontinuation of nanoxel without progression, single agent herzuma can be administered until progression)

NCT ID: NCT03319641 Completed - Clinical trials for Adenoid Cystic Carcinoma

PSMA-PET Imaging for Advanced ACC/SDC

Start date: October 25, 2017
Phase: N/A
Study type: Interventional

Diagnostic study which evaluates the level of PSMA expression in patients with locally advanced, recurrent and/or metastatic ACC/SDC of ≥18 years old with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are eligible for 177Lu-PSMA therapy